The BURAN Study of Buparlisib (AN2025) In Combination with Paclitaxel Compared to Paclitaxel Alone, in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Phase 3

Active, not recruiting

• Conditions: Recurrent or metastatic head and neck squamous cell carcinoma

• Registration Number: 2024-517251-12-00
• Lead Sponsor: Adlai Nortye USA Inc.

Brief Summary

To assess the overall survival (OS) of buparlisib in combination with paclitaxel compared to paclitaxel alone in patients with refractory, recurrent, or metastatic HNSCC.

Detailed Description

Not available

Study Timeline

• Study First Posted: 2024-09-24
• Last Update Posted: 2025-04-24

Recruitment & Eligibility

• Status: Ongoing, recruitment ended
• Sex: Not specified
• Target Recruitment: 202

Inclusion Criteria

Aged ≥18 years old.

Patients must apply highly effective contraception during and throughout the study, as well after the final dose of study treatment.

Able to provide informed consent obtained before any study related activities and according to local guidelines.

Patient has histologically and/or cytologically-confirmed HNSCC.

Patient has archival or new tumor tissue for the analysis of biomarkers

Patient has either progressive or recurrent disease after treatment with PDL1/PD1 based therapy for recurrent or metastatic disease.

Patient has received no more than two prior lines of systemic treatment for recurrent or metastatic HNSCC (single agent chemotherapy used as a radiosensitizer is not counted as a prior line of therapy).

Patient has measurable disease as determined per RECIST version 1.1. If the only site of measurable disease is a previously irradiated lesion, documented progression of disease and a four-week period since radiotherapy completion is required.

Patient has adequate bone marrow function and organ function as shown by the following: a. Absolute neutrophil count (ANC) ≥ 1.5 x 109/L. b. Hemoglobin ≥ 9 g/dL (which may be reached by transfusion). c. Platelets ≥ 100 x 109/L (which may be reached by transfusion). d. International normalized ratio (INR) ≤ 1.5. e. Calcium (corrected for serum albumin) within normal limits (WNL) or ≤ grade 1 severity according to NCI-CTCAE version 5.0 if judged clinically not significant by the Investigator. Patients concomitantly taking bisphosphonates or denosumab for calcium correction are eligible. f. Normal potassium and magnesium levels or clinically acceptable levels as per investigator’s judgement and confirmation. g. Alanine aminotransferase (AST) and aspartate aminotransferase (ALT) ≤ 1.5 x upper limit of normal (ULN) or < 3.0 x ULN if liver metastases are present. h. Total serum bilirubin ≤ ULN or ≤ 1.5 x ULN if liver metastases are present; or total bilirubin ≤ 3.0 x ULN with direct bilirubin below or within normal range in patients with well documented Gilbert’s Syndrome. Gilbert’s syndrome is defined as presence of episodes of unconjugated hyperbilirubinemia with normal results from cells blood count (including normal reticulocyte count and blood smear), normal liver function test results, and absence of other contributing disease processes at the time of diagnosis. i. Serum creatinine ≤ 1.5 x ULN or calculated and directly measured creatinine clearance (CrCL) > 30 mL/min. j. HbA1c ≤8%.

Patient has Eastern Cooperative Oncology Group (ECOG) performance status ≤1.

Exclusion Criteria

Patient has received previous treatment with any protein kinase B (PKB/AKT), mammalian target of rapamycin (mTOR) inhibitors, or phosphatidylinositol 3 kinase (PI3K) pathway inhibitors.

Patient has any of the following cardiac abnormalities: a. Symptomatic congestive heart failure within 12 months of the screening period. b. History of documented congestive heart failure (New York Heart Association functional classification III-IV) or documented cardiomyopathy and left ventricular ejection fraction (LVEF) <50% as determined by multiple gated acquisition (MUGA) scan or echocardiogram (ECHO). c. Myocardial infarction ≤six months prior to enrollment. d. Unstable angina pectoris. e. Serious uncontrolled cardiac arrhythmia. f. Symptomatic pericarditis. g. QT interval corrected according to the formula of Fridericia (QTcF) > 450 msec for males and > 470 msec for females, on the screening electrocardiogram (ECG).

Patient received treatment with a taxane as part of prior treatment for recurrent or metastatic disease

Patient has symptomatic central nervous system (CNS) metastases. Patients with asymptomatic CNS metastases may participate in this study. Patient must have completed any prior local treatment for CNS metastases ≥ 28 days prior to the start of study treatment (including radiotherapy) and must be on a stable low dose of corticosteroid therapy.

Patient has received wide field radiotherapy ≤ 4 weeks or limited field radiation for palliation ≤ 2 weeks prior to starting study treatment or who have adverse events which have not recovered to grade 1 or better from previous chemotherapy treatment (except alopecia, autoimmune endocrine events must be stable and controlled).

Patient has grade ≥ 2 neuropathy, colitis, pneumonitis, and uncontrolled endocrinopathies (e.g., hypothyroidism, diabetes with hemoglobin A1c > 8%) from previous treatment.

Patient has had major surgery within 14 days prior to starting study treatment or has not recovered from major side effects.

Patient is pregnant or nursing (lactating). Patients with elevated human chorionic gonadotrophin (hCG) at baseline that is judged to be related to the tumor are eligible if hCG levels do not show the expected doubling when repeated five to seven days later, or pregnancy has been ruled out by vaginal ultrasound.

Patient has received a live vaccine within 30 days of planned start of study therapy. Note: Seasonal influenza vaccines for injection are generally inactivated flu vaccines and are allowed; however intranasal influenza vaccines (eg, Flu-Mist®) are live attenuated vaccines, and are not allowed. Non-live COVID vaccinations/boosters may be administered during a patient’s participation of the trial, however it is recommended this not occur within 30 days of study start (C1D1) or during Cycle 1 for those patients randomized to the buparlisib arm. Patients are not to be excluded if administration of the non-live COVID vaccinations or boosters occurs within 30 days of a patient’s C1D1 or during cycle 1.

Patient is currently receiving increasing or chronic treatment (>5 days) with corticosteroids or another immunosuppressive agent. The following uses of corticosteroids are permitted: single doses; standard premedication for paclitaxel, topical applications (e.g., rash), inhaled sprays (e.g., obstructive airways diseases), eye drops, or local injections (e.g., intra-articular), or < 10 mg prednisolone or equivalent.

Patient is currently receiving warfarin or other coumarin-derived anti-coagulant, for treatment, prophylaxis, or otherwise. Therapy with heparin, low molecular weight heparin (LMWH), fondaparinux or new oral anticoagulants (NOACs) is allowed.

Patient has a known hypersensitivity and/or contraindication to paclitaxel, standard premedication for paclitaxel, or other products containing Cremophor®.

Patient has impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of study treatment (e.g., ulcerative diseases, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome, or small bowel resection).

Patient has other prior or concurrent malignancy except for the following: adequately treated basal cell or squamous cell skin cancer, or other adequately treated in situ cancer, early gastric or GI cancer resected completely by endoscopy procedures or any other cancer from which the patient has been disease free for ≥ 3years.

Patient has a history of non-compliance to any medical regimen or inability to grant consent.

Patient has other concurrent severe and/or uncontrolled medical conditions that would, in the Investigator’s judgment, contraindicate patient participation in the clinical study (e.g., active or uncontrolled severe infection, chronic active hepatitis, immunocompromised, acute or chronic pancreatitis, uncontrolled high blood pressure, interstitial lung disease, etc).

Patient has a known history of human immunodeficiency virus (HIV) infection (testing not mandatory)

Study & Design

• Study Type: Interventional clinical trial of medicinal product
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
The primary endpoint of this study is OS.		The primary endpoint of this study is OS.

Secondary Outcome Measures

Name	Time	Method
Efficacy: 1. PFS 2. Overall response rate (ORR) 3. Duration of response (DoR) 4. OS, PFS, ORR and DoR in subgroups		Efficacy: 1. PFS 2. Overall response rate (ORR) 3. Duration of response (DoR) 4. OS, PFS, ORR and DoR in subgroups
Safety: 1. AEs 2.Clinical laboratory tests		Safety: 1. AEs 2.Clinical laboratory tests
Exploratory Endpoints: Biomarkers		Exploratory Endpoints: Biomarkers

Trial Locations

Locations (60)

Clinique Saint-Pierre; 🇧🇪 Ottignies-Louvain-La-Neuve, Belgium

UZ Brussel; 🇧🇪 Jette, Belgium

Universitair Ziekenhuis Gent; 🇧🇪 Gent, Belgium

L'Hopital Prive Du Confluent; 🇫🇷 Nantes Cedex 2, France

Centre Hospitalier Universitaire De Bordeaux; 🇫🇷 Bordeaux Cedex, France

Centre Francois Baclesse; 🇫🇷 Caen Cedex 5, France

Centre Hospitalier Regional De Marseille; 🇫🇷 Marseille, France

Institut Regional Du Cancer De Montpellier; 🇫🇷 Montpellier Cedex 5, France

Centre Medico Chirurgical Ambroise Pare Hartmann; 🇫🇷 Neuilly-Sur-Seine, France

Centre Leon Berard; 🇫🇷 Lyon, France

Scroll for more (50 remaining)

Clinique Saint-Pierre

🇧🇪Ottignies-Louvain-La-Neuve, Belgium

Renaud Poncin

Site contact

+3210437241

philippe.pierre@cspo.be